Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.52 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.52 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.52 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.51 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.51 |
| ▸ | VNN1 | O95497 | 9/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1237189 | 0.82 | SRD5A2 (0.79) | SRD5A2CNR2CNR1CES2VNN1 | |
| SCHEMBL18286281 | 0.81 | KCNQ3 (0.67) | SRD5A2CNR1CES2KCNQ3KCNQ2 | |
| SCHEMBL27623752 | 0.80 | RECQL (0.47) | SRD5A2 | |
| SCHEMBL39874 | 0.80 | KCNQ3 (0.70) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL4227036 | 0.79 | KMT2A (0.57) | SRD5A2CNR2CNR1 | |
| SCHEMBL28565479 | 0.78 | SRD5A2 (0.73) | SRD5A2CNR2CNR1CES2VNN1 | |
| SCHEMBL1044812 | 0.77 | SRD5A2 (0.83) | SRD5A2CNR2CNR1CES2VNN1 | |
| SCHEMBL40183 | 0.77 | MEN1 (0.68) | NPSR1 | |
| SCHEMBL16632079 | 0.77 | VNN1 (0.48) | SRD5A2CNR2CNR1VNN1 | |
| SCHEMBL2941622 | 0.76 | SRD5A2 (0.81) | SRD5A2CNR2CNR1CES2VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208907-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208907-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208907-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| EP-4330232-A1 | GPR52 MODULATORS AND METHODS OF USE | Neurocrine Biosciences, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022232017-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208907-A1 | GPR52 MODULATORS AND METHODS OF USE | GPR52, GPR68, GPR35 | SRD5A2 997/4885CNR2 30/4885CNR1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.